Integrating the anti-VEGF - A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer

Clinical Colorectal Cancer

Volumn 4, Issue SUPPL. 2, 2004, Pages

  Hurwitz, Herbert ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

5 fluorouracil; Antiangiogenic therapy; Capecitabine; Irinotecan; Oxaliplatin

Indexed keywords

ANTICOAGULANT AGENT; BEVACIZUMAB; CAPECITABINE; EPIDERMAL GROWTH FACTOR; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLACEBO; VASCULOTROPIN; VASCULOTROPIN A; WARFARIN;

ADVANCED CANCER; ANASTOMOSIS DEHISCENCE; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTERY THROMBOSIS; BLEEDING; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INFUSION; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; EPISTAXIS; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HEMATOTHORAX; HUMAN; HYPERTENSION; INFECTION; LEUKOPENIA; LUNG EMBOLISM; LUNG HEMORRHAGE; MEDICAL RESEARCH; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PRIMARY HEALTH CARE; PROTEIN EXPRESSION; PROTEINURIA; RANDOMIZATION; REVIEW; RISK ASSESSMENT; STOMACH ULCER; STOMATITIS; STROKE; THROMBOCYTOPENIA; THROMBOSIS; VOMITING; WOUND DEHISCENCE; WOUND HEALING IMPAIRMENT;

EID: 7444224685     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2004.s.010     Document Type: Article

References (13)

1. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:60-65.
2. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
3. Fyfe GA, Hurwitz H, Fehrenbacher L, et al. Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups. Proc Am Soc Clin Oncol 2004; 23:274 (Abstract #3617).
4. DeVore RF, Fehrenbacher L, Herbst RS, et al. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIb/IV NSCLC. Proc Am Soc Clin Oncol 2000; 19:485a (Abstract #1896).
5. Scappaticci F, Fehrenbacher L, Cartwright, T, et al. Analysis of wound healing and bleeding post-surgery in metastatic colorectal cancer patients treated with bevacizumab. In: Proceedings of the 2004 Gastrointestinal Cancers Symposium; January 22-24, 2004; San Francisco, CA. Abstract #235.
6. Scappaticci F, Fehrenbacher L, Cartwright T, et al. Bevacizumab does not increase wound healing/bleeding complications when given 28-60 days following primary cancer surgery. Proc Am Soc Clin Oncol 2004; 23:253 (Abstract #3530).
7. Hambleton J, Novotny WF, Hurwitz H, et al. Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation. Proc Am Soc Clin Oncol 2004; 23:252 (Abstract #3528).
8. Avastin [package insert]. South San Francisco, CA: Genentech, 2004.
9. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30.
10. Giantonio BJ, Catalano PJ, Meropol NJ, et al. The addition of bevacizumab (anti-VEGF) to FOLFOX4 in previously treated advanced colorectal cancer (advCRC): An updated interim toxicity analysis or the Eastern Cooperative Oncology Group (ECOG) study E3200. In: Proceedings of the 2004 Gastrointestinal Cancers Symposium; January 22-24, 2004; San Francisco, CA. Abstract #241.
11. Phase III randomized study of oxaliplatin and bevacizumab (Avastin ™) with fluorouracil and leucovorin calcium or capecitabine in patients with advanced colorectal cancer. Bethesda, MD: National Cancer Institute. Available at: www.cancer.gov/clinicaltrials/view_clinicaltrials.aspx?version= healthprofessional&cdrid=304771&protocolsearchid=908619. Accessed June 17, 2004.
12. Capecitabine in combination with oxaliplatin (XELOX) with or without bevacizumab vs. fluorouracil/leucovorin with oxaliplatin (FOLFOX-4) with or without bevacizumab as first-line treatment for patients with metastatic colorectal cancer. Bethesda, MD: National Cancer Institute. Available at: www.cancer.gov/search/ViewClinical-Trials.aspx?cdrid=350345&version= HealthProfessional&protocolsearchid=1125856. Accessed Sept 8, 2004.
13. Phase III randomized study of fluorouracil, leucovorin calcium, and oxaliplatin versus capecitabine and oxaliplatin with or without bevacizumab in patients with locally advanced, metastatic, or recurrent colorectal cancer. Bethesda, MD: National Cancer Institute. Available at: www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=330000&version= HealthProfessional&protocolsearchid=1125856. Accessed June 17, 2004.